














Review Article

Phytochemical Constituents, Biological Activities, and Health-Promoting Effects of the *Melissa officinalis*

Javad Sharifi-Rad ¹, Cristina Quispe ², Jesús Herrera-Bravo ^{3,4}, Muhammad Akram,⁵ Wafa Abbaass,⁵ Prabhakar Semwal,^{6,7} Sakshi Painuli,^{6,8} Dmitry Alekseevich Kononov,⁹ Mary Angelia Alfred,¹⁰ Nanjangud Venkatesh Anil Kumar ¹⁰, Muhammad Imran,¹¹ Muhammad Nadeem,¹² Barbara Sawicka ¹³, Piotr Pszczółkowski ¹⁴, Bernadetta Bienia ¹⁵, Piotr Barbaś ¹⁶, Shafi Mahmud,¹⁷ Alessandra Durazzo ¹⁸, Massimo Lucarini ¹⁸, Antonello Santini ¹⁹, Miquel Martorell ^{20,21} and Daniela Calina ²²

¹Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador

²Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, Iquique 1110939, Chile

³Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Chile

⁴Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile

⁵Department of Eastern Medicine, Government College University Faisalabad, Pakistan

⁶Department of Life Sciences, Graphic Era (Deemed to be University), Dehradun (248002), Uttarakhand, India

⁷Uttarakhand State Council for Science and Technology, Vigyan Dham, Dehradun, 248007 Uttarakhand, India

⁸Himalayan Environmental Studies and Conservation Organization, Prem Nagar, Dehradun, 248001 Uttarakhand, India

⁹Department of Pharmacognosy and Botany, Pyatigorsk Medical and Pharmaceutical Institute, A Branch of Volgograd State Medical University Ministry of Health of the Russian Federation, Kalinina av.11, Pyatigorsk 357532, Russia

¹⁰Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal 576104, India

¹¹University Institute of Diet and Nutritional Sciences, Faculty of Allied Health Sciences, The University of Lahore-Lahore, Pakistan

¹²Department of Environmental Sciences, COMSATS University Islamabad, Vehari Campus, Pakistan

¹³Department of Plant Production Technology and Commodities Science, University of Life Sciences in Lublin, Poland, Akademicka 13 Str., 20-950 Lublin, Poland

¹⁴The Experimental Station for Variety Assessment of the Central Plant Research Center Uhnin, ZDOO Uhnin, 21-211 Dębowa Kłoda, Poland

¹⁵Department of Herbal Medicine, Carpathian State University in Krosno, Poland, Dmochowskiego 12 Str., 38-400 Krosno, Poland

¹⁶Department of Potato Agronomy, Plant Breeding and Acclimatization Institute-National Research Institute, Jadwisin Research Center, Poland

¹⁷Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh

¹⁸CREA-Research Centre for Food and Nutrition, Via Ardetina 546, 00178 Rome, Italy

¹⁹Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy

²⁰Department of Nutrition and Dietetics, Faculty of Pharmacy and Centre for Healthy Living, University of Concepción, Concepción, Chile

²¹Unidad De Desarrollo Tecnológico (UDT), Universidad De Concepción, Concepción, Chile

²²Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania

Correspondence should be addressed to Javad Sharifi-Rad; javad.sharifrad@gmail.com, Nanjangud Venkatesh Anil Kumar; nv.anil@manipal.edu, Antonello Santini; asantini@unina.it, Miquel Martorell; martorellpons@gmail.com, and Daniela Calina; calinadaniela@gmail.com

Received 10 September 2021; Revised 14 November 2021; Accepted 1 December 2021; Published 31 December 2021

Academic Editor: Lei Chen

Copyright © 2021 Javad Sharifi-Rad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicinal plants are being used worldwide for centuries for their beneficial properties. Some of the most popular medicinal plants belong to the *Melissa* genus, and different health beneficial effects have already been identified for this genus. Among these species, in particular, the *Melissa officinalis* L. has been reported as having many biological activities, such as antioxidant, antimicrobial, antitumour, antiviral, antiallergic, anti-inflammatory, and also flatulence inhibiting effects. The beneficial properties of the *Melissa officinalis*, also known as “lemon balm herb”, can be related to the bioactive compounds such as terpenoids, alcohols, rosmarinic acid, and phenolic antioxidants which are present in the plant. In this updated review, the botanical, geographical, nutritional, phytochemical, and traditional medical aspects of *M. officinalis* have been considered as well as *in vitro* and *in vivo* and clinically proven therapeutic properties have been reviewed with a special focus on health-promoting effects and possible perspective nutraceutical applications. To evidence the relevance of this plant in the research and completely assess the context, a literature quantitative research analysis has been performed indicating the great interest towards this plant for its beneficial properties.

1. Introduction

Medicinal plants and herbs have been used worldwide in the management of different diseases [1, 2]. The search for new antibacterial, antiviral, anticancer agents from natural sources has been intensified due to the reduction of currently available therapy in subjects who do not qualify for conventional pharmacological therapy and the emergence of drug-resistant strains [3, 4]. Recently, the nutraceutical area has been exploited playing a key role in the development of new phytocomplex derived from food and plant-derived compounds [5, 6].

An example of popular medicinal plants with recognized beneficial effects on human health belongs to the *Melissa* genus [7]. Botanically, this plant can be identified as follows: genus *Melissa* L. belongs to kingdom: Plantae, family: Lamiaceae, and subfamily: Nepetoideae, with numerous species, four of which are *Melissa axillaris* (Benth.) Bakh. f., *Melissa flava* Benth., *Melissa officinalis* L. (lemon balm), and *Melissa yunnanensis* C.Y. Wu & Y.C. Huang which is recognized worldwide for its relevance [8, 9]. These species are found in the area from Central Asia, Western Asia, Southern Europe, and Northern Africa up to the islands of Macaronesia [8]. Only one species grows in Europe—the *M. officinalis* known as lemon balm. In nature, these plants grow in bright thickets [10].

Currently, this most popular and known species, the *M. officinalis*, is cultivated around the world [11–13]. Even if the *M. officinalis* is indigenous to Southern Europe, the Mediterranean region, Western Asia, and North Africa, this species is now cultivated worldwide. In India, lemon balm is cultivated in Kashmir, Uttrakhand, and some parts of South India. There are two subspecies: *M. officinalis* subspecies *M. officinalis*, the commonly cultivated lemon balm; and *M. officinalis* subspecies *altissima*, naturalized in New Zealand and known as the bush balm. The *M. officinalis* subspecies *officinalis* is known for its lemon fragrance [12, 14].

Nowadays, the increasing demand for medicinal plants and herbs triggers the interest in quality and safety aspects since herb and plants pathogens, e.g., microfungi, could cause serious health issues if present in these plants decreasing also their quality [15, 16]. Species like *Fusarium* sp.,

Alternaria sp., and *Penicillium* sp. can produce secondary metabolites (mycotoxins) which may represent a healthy treat as it happens also in plants, food, and feed contaminated by these metabolites which represent a challenge for the decontamination due to their presence and their identification (Nazhand et al., 2020; Santini et al. 2009; Mikusova et al. 2013; Mikusova et al. 2010; Santini et al., 2009).

2. *Melissa officinalis* and Its Health Benefits: Literature Quantitative Research Analysis

A search for *Melissa officinalis* and its relationship with health was carried out employing the Scopus database. The Scopus online database (<https://www.scopus.com/home.uri>, accessed on 4 September 2021) was utilized to extract bibliometric data using the search string: TITLE-ABS-KEY (“*Melissa officinalis*” OR “lemon balm” AND “Health*”).

Publications mentioning the relevant words or their derivatives in the title, abstract, or keywords were identified throughout the applied search strategy [17]. The parameters evaluated were as follows: trends of publications, document type, authorship, and country/region. For the basic analyses, the functions of the Scopus web online platform named “Analyze” and as “Create Citation Report” were utilized. Moreover, the “full records and cited references” were exported to VOSviewer software for additional processing [18].

The terms/words utilized in the titles, abstracts of publications, and keywords of publications were analyzed by the VOSviewer software (v.1.6.16, 2020); the paragraphs were broken down into words and phrases and linked to the publications’ citation data, to visualize the results as bubble map. In this term map, the bubble size indicates how frequently a term is mentioned in the articles. Two bubbles are positioned more closely to each other reflecting that the terms coappeared more often in the selected publications. The average citations per publication (CPP) is given by the colour of a bubble. To simplify the bubble map, words/terms that appeared in at least 5 of the publications were analyzed and visualized. Of the 5772 keywords, 436 met the selected threshold, and 3 of them were manually excluded.

Two hundred seventy publications were returned by the search: they covered the time range from 1984 to 2021 and were cited collectively by 5682 documents. Publications trends of the *Melissa officinalis* and health research are reported in Figure 1.

The distribution of the types of documents relative to the publications retrieved is shown in Figure 2. “Article” accounts for 75.9% and “Review” for 18.1%, followed by Book Chapter” (1.9%) and “Conference Paper” (1.5%). The most cited “Article” is a placebo-controlled trial for studying the value of aromatherapy with essential oil of *Melissa officinalis* for agitation in people with severe dementia, whereas the most cited “Review” is addressed on Alzheimer’s disease and vascular dementia in developing countries, with regard on the use of traditional diet and medicinal plants.

Figure 3 reports the most productive authors.

Figure 4 reports, respectively, the most productive countries/territories. Regarding countries/territories, the United States ($n = 30$) was the most productive country, followed by Iran ($n = 28$) and the United Kingdom ($n = 27$).

Four hundred and the thirty-third of terms in total were obtained from the literature quantitative analysis on publications, and they are visualized as a term map shown in Figure 5. Plant extracts, *M. officinalis* extract, medicinal plants, phytotherapy, herbal medicine, and traditional medicine are among the top recurring terms.

3. Traditional Medicinal Uses

M. officinalis is a medicinal plant that has been used for a long time in different ethnomedical approaches especially in traditional medicine for the treatment of several diseases. The traditional uses of *M. officinalis* have been reported mostly in European Countries, the Mediterranean region, and the Middle East Countries.

Records concerning the use of *M. officinalis* date back over 2000 years, with entries in the *Historia Plantarum* (approximately 300 B.C.). Its use has been exploited for the treatment of many health syndromes including neurological, central nervous system, cardiovascular, antimicrobial, antimalignant, antidepressant, and respiratory and also as a memory enhancer for dementia-affected subjects. In the seventh century, its cultivation and use spread throughout Europe [19]. An early recommendation by Paracelsus (1493–1541) suggested that it could be used for “all complaints supposed to proceed from a disordered state of the nervous system” [20].

M. officinalis is reputed to alleviate melancholia and neuroses, and the plant was considered to promote long life and to restore memory in traditional European medicine [21]. In 1679, Lonicerus claimed that *M. officinalis* (the aerial parts) taken on an empty stomach quickens the senses, brightens the mind, and improves the memory. It aids shaking limbs caused by stroke and helps retrieve the lost ability to speak [22, 23]. Moreover, in 1751, the herbalist John Hill described *M. officinalis* as “good for disorders of the head and stomach” [21], and in the Ayurveda holistic medicine approach, it was claimed that *M. officinalis* sharpens memory [24]. *M. officinalis* is a cultivated and introduced herb in the Call-

ejon de Huaylas (Peru), used as a sedative, and hypotensive [25]. Herbal medicine has been traditionally practiced by indigenous healers in Bolivia for hundreds of years, an area where due to the great geographical and ecological diversity, thousands of native plants are utilized against different types of diseases [26].

Often the traditional use of *M. officinalis* is mostly combined with other medicinal plants. For instance, around 400 prescriptions are containing *M. officinalis* in Iranian Traditional Medicine [27]. An ethnobotanical study of the medicinal use of wild and cultivated plants in the middle, southern, and western Bosnia and Herzegovina showed that *M. officinalis* is part of the combined teas for the increase of digestion (with *Acorus*, *Foeniculum*, *Matricaria*, and *Mentha*), a decrease of spasms (with *Agrimonia*, *Frangula*, *Mentha*, *Teucrium chamaedrys*, and *Teucrium montanum*), and insomnia (with *Robinia*) [28].

Medicinal plants which can be used as tools against anxiety and as antidepressant drugs according to the ethnobotanical knowledge in Shahrekord (Iran) include *M. officinalis*, proven to be effective on anxiety and depression [29]. In the Unani system of medicine, its grass and seeds are used in epilepsy, paralysis, Bell’s palsy, arthritis, mastitis, and halitosis; its syrup and distillate are made for different ailments [30].

M. officinalis is used as a sedative, and for its digestive properties in Serbia, it is used for nervous anxiety, depression, tension headaches, and indigestion (as a tea-like beverage that is drunk after a meal). It is also used for diseases related to the liver and gallbladder, jaundice, and complaints related to the heart and blood vessels, and it is administered as an infusion (tea). As an example of its use, a recipe of a tea blend for strengthening nerves consists of equal quantities of lemon balm, valerian, hops, hawthorn, wild thyme, and peppermint. For peaceful sleep, pillows are filled with the dried aerial parts (northern and western Serbia). It is also used to lure bees—beekeepers rub hives (in eastern Serbia) [31].

An ethnobotanical survey of the wild plants of Lebanon showed that *M. officinalis* is harvested and used as a spice, herbal tea, condiment, medicinal plant, and in perfumes [32]. In Central Italy, *M. officinalis* shoots are used in alcoholic beverages [33]. Ethnobotanical evidence suggests that the herb of *M. officinalis* is used for the skin and body care. Lemon balm hydrosol is added to clay masks for skin healing. Fresh leaves add a nice flavour to many dishes, oils, vinegar, and herbal liqueurs. Fresh or dried leaves are used to prepare a refreshing tea, consumed either cold or hot. The fresh leaves and flowers are used for the stuffing of vegetables, fruit salads, bean dishes, meat, and fish [12]. It is noteworthy that the traditional use of this plant is similar in different cultures: for example, treatment of mental disorders, especially anxiety and depression, memory improvement, and relief of heart disease. As can be seen from the data reported in Table 1, the above-ground part and the leaves of the plant have traditionally been used more often; from them, mainly, an infusion, tea, or decoction can be prepared.

Table 1 summarizes some relevant information on the traditional use of *M. officinalis* in different countries.




FIGURE 1: Publication and citations trends of *Melissa officinalis* and health research (bibliometric data were extracted from the Scopus online database).




FIGURE 2: Distribution of type document (bibliometric data were extracted from the Scopus online database).

4. Chemical Composition

The most important class of plant components are alkaloids, tannins, flavonoids, saponins, and phenolic compounds [10, 12, 79]. The variety of these bioactive molecules makes

them a promising candidate for the development of nutraceuticals and cosmeceuticals [10, 80]. This plant and its parts can be used in the food, pharmaceutical, cosmetic, and other industries which are interested in aromatic plants and essential oils.

4.1. Polyphenols. Regarding the polyphenolic profile of extracts, Awad et al. [81] isolated rosmarinic acid, ursolic acid, and oleanolic acid from the methanol extract of aerial parts of *M. officinalis*.

Astani et al. [82] isolated caffeic acid, *p*-coumaric acid, and rosmarinic acid. Nitric acids A and B, antioxidant active compounds, have been identified in the dried leaf of *M. officinalis* by Kamdem et al. [83] and quantified. The leaves were extracted in 70% ethanol, which resulted in the following compounds quantified using liquid chromatography-mass spectrometry (LC-MS): gallic acid, chlorogenic acid, caffeic acid, rosmarinic acid, ellagic acid, rutin, isoquercitrin, quercetin, and kaempferol. Aubert et al. [84] identified the following compounds from hydroethanolic leaf extract of *M. officinalis* using LC-MS: tartaric acid, quinic acid, malic acid, citric acid, succinic acid, danshensu, caftaric acid, salicylic acid, caffeic acid, lithospermic acid A, chicoric acid, luteolin 3'-*O*- β -D-glucuronide, rosmarinic acid, 3'-*O*-(8'-*Z*-caffeoyl)rosmarinic acid, and ethyl caffeate.

Another example has been reported by Binello et al. [85] where an efficient and selective green extraction of polyphenols from lemon balm has been proposed using ultrasound and microwave-assisted extraction protocols. Their efficiency and selectivity have been compared: rosmarinic acid was the main component of the phenolic fractions in all cases, whereas ethanol was the best solvent for both ultrasound and microwave-assisted extraction procedures [85].




FIGURE 3: Most productive authors (bibliometric data were extracted from the Scopus online database).




FIGURE 4: Most productive countries/territories (based on data from Scopus).

4.2. *Essential Oil*. Concerning the characterization of the essential oil, several works studied the composition of the aerial flowering parts of *M. officinalis* [80, 86–88].

For instance, Acevedo et al. [80] isolated the following essential oils: eugenol, caryophyllene, α -caryophyllene, 3-methyl-4-isopropyl phenol, and germacrene D. Abdellatif et al. [89, 90] hydro distilled the dried leaves of *M. officinalis* and identified the following essential oils using gas chromatography coupled to mass spectrometry (GC-MS): 1-octen-3-ol, 6-methyl-5-hepten-2-one, myrcene, (*Z*)- and (*E*)- β -ocimene, linalool, *n*-nonanal, *cis*- and *trans*-rose oxide, *trans*-limonene oxide, camphor, citronellal, *cis*-chresonty-

nol, menthol, isomenthol, nerol, neral, piperitone, geraniol, geranial, dihydrocitronellol acetate, α - and β -cubebene, geranyl acetate, α -copaene, β -caryophyllene, α -humulene, germacrene D, (*E*)- β -ionone, valencene, (*E*)-nerolidol, caryophyllene oxide, 1-hexadecene, 14-hydroxy-9-epi-(*E*) caryophyllene, *n*-eicosane, *n*-heneicosane, methyl citronellate, and camphene. Barakat et al. [91] identified the following compounds by hydrodistillation of dried leaves of *M. officinalis* using GC-MS: (*E*)-ocimene, α -campholenal, pino-carvone, terpinen-4-ol, cuminaldehyde, thymol, *p*-mentha-1,4-diene-7-ol, α -copaene, β -bourbonene, panasinsene, (*E*)-caryophyllene, amorpho-4,11-diene, γ -muurolene, elemol,




FIGURE 5: Term map for relationships of *Melissa officinalis* and health research. The number of publications was represented by bubble size. The citations per publication (CPP) was given by bubble colour. Two bubbles are closer to each other reflecting that the terms coappeared more frequently (bibliometric data were extracted from the Scopus online database and elaborated by VOSviewer software).

caryophellene oxide, humulene epoxide II, elemol acetate, α -terpinolene, trans-pinocarveol, *cis*-chrysanthenol, (*E*)-citral, carvacrol, decadienal, α -copaene, β -bourbonene, and isotorquatone. Efremov et al. [92] extracted the essential oils by exhaustive water and steam distillation from the above-ground part of *M. officinalis*.

Rehman et al. [93] identified from *M. Officinalis* fresh leaves using the headspace solid-phase microextraction (HS-SPME) coupled with GC-MS with the following compounds, all with interesting activity: β -pinene, artemiseole, 1-octen-3-ol, 3-octanol, 6-methyl-5-hepten-2-one, D-3-carene, (*Z*)- β -ocimene, linalool, *cis*-rose oxide, *trans*-rose oxide, *cis*-verbenol, limonene oxide, citronellal, isopulegone, myrtenol, citronellol, geraniol, (*Z*)-citral, methyl geranate, (*E*)-citral, citronellyl acetate, α -copaene, geranyl acetate, β -caryophyllene, α -bergamotene, α -humulene, germacrene D, α -farnesene, and D-cadinene. In the perspective of an eco-friendly sustainable procedure, it is worth to mention the work of Khalili et al. [94], which reported the solvent-free extraction of essential oils from *M. officinalis*. The compounds identified by GC-MS are linalool, (*Z*)- and (*E*)-citral, neryl acetate, β -bourbonene, β -bourbonene, α -humulene, germacrene D, α -muurolene, and caryophyllene oxide.

5. Biological Activities of *Melissa officinalis*: Molecular Evidences from Preclinical Studies

The biological properties of the lemon balm herb can be associated with the presence and combined action of bioactive compounds such as terpenoids, rosmarinic acid and

phenolic antioxidants. The most important bioactive compounds from *M officinalis* and their correlation with biological activities are shown in Figure 6.

5.1. Effects on the Central Nervous System

5.1.1. Neuroprotective. In several *in vivo* and *in vitro* studies, the neuroprotection and beneficial treatment of several nervous disorders were attributed to the administration of *M. officinalis*.

Methanolic extract of *M. officinalis* administered to PC12 was reported to provide cell protection against H_2O_2 toxicity in lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [95]. Moreover, reduction in the intracellular formation of reactive oxygen species and neuroprotection was attributed to the administration of aqueous and methanolic extracts *M. officinalis* [96]. Lemon balm was reported to have neuroprotective activity against 3,4-methylenedioxy-methamphetamine-induced cell apoptosis in response to free radicals.

Soodi et al. [97] carried out an *in vivo* study on rats to validate the significant effect of *M. officinalis* as a potential agent for improving brain health. The study determined that the 80% ethanol extract of *M. officinalis* improved memory in induced memory-impaired clinical rats and concluded that *M. officinalis* extract has probable therapeutic potential in alleviating memory loss.

5.1.2. Antidepressant. Ethanolic extract of *M. officinalis* was orally administered in three different concentrations of 30,

TABLE 1: Traditional uses of *Melissa officinalis* in different Countries.

Country/region	Organ/part of plant	Mode of application	Traditional uses	References
Argentina/San Martin de los Andes	—	—	Sedative	[34]
Austria	Leaves	Internal as tea, external essential oil	Treatment of diseases of the gastrointestinal tract, nervous system, liver and bile; food	[35]
Bolivia/Qampaya	Leaves	Infusion	Psychological problems, heart problems	[26]
Bosnia and Herzegovina/Javor Mountain	Aerial parts	Infusion	Insomnia, digestive disorders; spasms, respiratory infections	[36]
Brazil/Santa Catarina	Leaves	—	Colic pain in babies, gastrointestinal, to reduce blood pressure, influenza	[37]
Brazil	Leaves	Decoction	Calmative, migraine, sedative	[38]
	Leaves	Decoction	Sedative, tranquilizer	
Bulgaria	Herb	Decoction	Hypertonia	[39]
	Herb	Decoction	Improves appetite	
Catalonia/L'Alt Emporda and Les Guilleries	Leaves	Infusion	Sedative	[40]
Denmark	Aerial parts	—	Against sleeplessness caused by heartbreak; against melancholy and sadness	[27, 41]
Ecuador/Loja and Zamora-Chinchi	Stems, leaves	Infusion	Relaxant, insomnia	[42]
Ecuador/Loja	Whole plants, branches	Crushed	Nerves	[43]
Greece/Macedonia	Leaves of <i>Melissa officinalis</i> subsp. <i>altissima</i> (Sm.) Arcang.	Decoction or infusion	As sedative; used as a decoction in combination with <i>Crataegus monogyna</i> Jacq. for the prevention of cardiovascular diseases	[44]
Iraq	Leaves	Herbal tea	Diuretic, analgesic; for headache, toothache, galactogen	[45]
Iraq/Hawraman	Leaves	—	Used as a wrap in dolma preparation	[46]
Iran/Chaharmahal and Bakhtiari (Shahrekord)	Aerial parts	—	Anxiety, depression	[29]
Iran/North Khorasan	Flowers, leaves	Infusion	To strengthen the memory, nerve tonic, hypnotic, antistress, sedative, anticonvulsive	[47]
Iran/Fars (Arjan-Parishan)	Leaves, seeds	Decoction	Sedative	[48]
Iran/Sistan, Baluchistan	Leaves	Decoction	Diuretic, sedative	[49]
Iran/Kermanshah	Aerial parts	Decoction	Antihistamine and antipruritus, diabetes control	[50]
Italy/Campania (Benevento Sannio)	Leaves, flowers	—	Antispasmodic, antihysterical, and tonic	[51]
Italy/Umbria	Leaves, shoots	—	Alcoholic beverages; boiled; fried in fat, without or with beaten eggs, risotto	[33]
Italy/marches	Leaves	Compress of crushed fresh leaves	To heal insect bite	[52]
Italy/Valvestino	Leaves	Poultice	Wound healing	[53]
Italy/Abruzzo, Lazio, Molise National Park	Aerial parts, leaves	Decoction	The decoction is used to favour digestion, lower blood pressure and for calming (also in case of emotional illness)	[54]
		—	An aromatic herb used as a beef condiment	

TABLE 1: Continued.

Country/region	Organ/part of plant	Mode of application	Traditional uses	References
Italy/Sardinia	Leaves Herb	Tea —	Helps relieve premenstrual symptoms Nervous agitation, sleeping problems, functional gastrointestinal complaints, menstrual cramps, and urinary spasms	[55]
Italy/Salento	Leaves	—	Seasoning in many dishes	[56]
Jordan	Aerial parts	Infusion	Sedative, carminative, antispasmodic, and digestive	[57]
Jordan	Aerial parts	—	Abdominal pain, gynaecological disorders, arthritis	[58]
Kosovo/Pejë and Deçan	Areal parts	Infusion Decoction	For treating abdominal pains during pregnancy Neuro-relaxant	[59]
Lebanon/Jabal Moussa Bioserve	Leaves —	— —	Strengthen the heart, migraine, stomach disorders and memory Harvested as a spice, herbal tea, condiment, medicinal plant and perfumes	[60] [32]
Macedonia	Aerial parts (fresh)	Decoction	Nervous system, focus, concentration, and relaxation, used as a spice	[61]
Morocco/Ksar Lakbir	Aerial parts	Infusion	As spasmolytic, depurative and cholagogue	[62]
Morocco/ Peru/Ancash	Whole plants Leaves	— Infusion	Anti-diarrhea, astringent, febrifuge Sedative and hypotensive	[63] [25]
Portugal/Trás-os-Montes	Aerial parts, stems, flowers, fresh or dried.	Infusion	Relaxation (nervousness, insomnia, spasms and nervous indigestion); intestinal gases and pain; digestion and bile stimulation; fever, headache and influenza; stomach ache and gastritis; for the heart; memory stimulation.	[64]
Republic of Macedonia/Sharr Mountain	Leaves	Tea, essential oil	Heart problems, headaches	[65]
Russia	Herb	Infusion	To stimulate the appetite and gastrointestinal tract; for nausea, vomiting, painful menstruation, cardiac neurosis	[66]
Serbia/Kopaonik Mountain	Aerial parts	Tea	Sedative, relaxing, digestive properties; internally taken for nervous anxiety, depression, tension headaches and indigestion (tea taken after meal)	[67]
Spain/Alava (Valdegovía, Valle de Arana, Izki)	Aerial parts	Infusion Herbal tea: aerial parts, infusion, alone or with Hypericum perforatum	Bronchitis, stomach pain Relaxant, depression	[68]
Turkey/K. Maras Turkey/Bayramic	Leaves Leaves	Decoction —	Stomach diseases, nephritis, cardiovascular diseases, forgetfulness, diabetes, cold, flu, bronchitis, enteritis	[69] [70]
Turkey/Antakya	Aerial parts <i>Melissa officinalis</i> L. subsp. <i>inodora</i> Bornm.	Infusion Decoction	Antiseptic, cold, diabetes, antispasmodic Heart diseases Stomach pains, gastritis, ulcer, sedative	[71]

TABLE 1: Continued.

Country/region	Organ/part of plant	Mode of application	Traditional uses	References
Turkey/Kumluca (Antalya)	Aerial parts of <i>Melissa officinalis</i> L. subsp. <i>officinalis</i>	Infusion	Relaxing, stomach disorders, intestinal disorders, cardiovascular disease, digestive, diarrhea, migraine, analgesic	[72]
Turkey/Anatolia	Leaves of <i>Melissa officinalis</i> subsp. <i>officinalis</i>	Decoction as tea and oils are applied to the pain region	Sedative	[73]
Turkey/Uzunköprü	Aerial parts	Infusion	Diabetes, cold, insomnia	[74]
Turkey/Samsun (Yeşilirmak Delta)	Leaves of <i>Melissa officinalis</i> subsp. <i>officinalis</i>	—	Soothes insect bite, headache, indigestion, nausea, sedative	[75]
Turkey/Osmaniye (Bahçe and Hasanbeyli)	Aerial parts of <i>Melissa officinalis</i> L. subsp. <i>inodora</i> Bornm	Infusion	Sedative, gastric and carminative	[76]
Turkey/Kahramanmaraş (Andirin)	Aerial parts of <i>Melissa officinalis</i> L. subsp. <i>inodora</i> Bornm	Infusion, decoction	Pain in head, cardiac, stomach and intestinal disease	[77]
Uzbekistan/Tashkent (Chatkal Biosphere Reserve)	Whole plants	—	Epilepsy, mental illness, diuretic, digestive, fevers and colds, indigestion associated with nervous tension, hyperthyroidism, depression, mild insomnia, epilepsy, headaches, toothaches, flatulence, colic, nausea, nervousness, anaemia, vertigo, syncope, malaise, asthma, bronchitis, amenorrhoea, cardiac failure, arrhythmias, depression, psychosis, hysteria, ulcers, wounds, against Alzheimer disease, sedative, anti-inflammatory, hepatoprotective, digestive, antiviral, antilipidaemic, anxiolytic	[78]




FIGURE 6: Summarized scheme with the most important bioactive compounds from *M. officinalis* and their correlation with biological activities.

100, and 300 mg/kg on a period of 10 days to Wistar rats and forced swimming and elevated plus-maze, and open field tests evaluated their behavioural effects [98]. Moreover, comparative effects against diazepam and fluoxetine were also evaluated. In the elevated plus-maze test, the percentage results in rats with subacute *M. officinalis* ethanol extract were remarkably higher than that in vehicle-treated animals but similar as in the diazepam-treated group, irrespective of the treatment duration. In the forced swimming test, the duration of immobility was reported lower in rats treated with the *M. officinalis* than that of the vehicle-treated group. In the 10-day treatment period, the antidepressant activity of fluoxetine was significantly higher than that of lemon balm [98].

5.1.3. Anxiolytic. Anxiety is a pathological emotional state characterized by anxiety, fear of the possibility of imminent danger or failure and over time natural remedies have proven beneficial [4, 99, 100]. Studies have shown that the anxiolytic effect of *M. officinalis* is dose dependent, and the responsible biocompounds are rosmarinic acid, pentacyclic triterpenes, and oleanolic and ursolic acids. Methanolic extract of *M. officinalis* was administered to the rat brain [101]. Rosmarinic acid, among the main components of the *M. officinalis*, was reported to have extensive γ -Aminobutyric Acid Transaminase (GABAT) inhibition medicinal properties. *In vivo* administration of aqueous extract of *M. officinalis* along with *P. caerulea* was reported to demonstrate anxiolytic activity through reduction in corticosterone (physiological stress mediator) level [27, 102, 103].

5.2. Antidiabetic. Chemical constituents of *M. officinalis*, oleanolic acid were reported to have potential antidiabetic pharmacological activity by survival and preservation of

pancreatic β -cells along with protection against diabetic complications. Hence, lipophilic triterpenoids in combination with the ethanolic extract of the plant have been proven as latent antidiabetic agents [27, 102].

Ethanolic extract of *M. officinalis* (0.6 mg/mL) was reported to induce cell-specific peroxisome proliferator-activated receptor (PPAR) gene expression to human primary adipocytes. However, replication of the same effect in clinical conditions needs further studies with lower doses which are more likely to be administered in humans [104]. Ethanolic extract of *M. officinalis* ethanol (200 mg/kg) was administered to obese mice with known case of insulin resistance for 6 weeks, and a significant reduction in glucose level, weight reduction, and insulin resistance was reported [105].

Alcoholic extract of *M. officinalis* has been reported to have antihyperlipidemic effects through inhibition of cholesterol synthesis and its secretion [106]. Moreover, the ethanolic leaf extract of *M. officinalis* was reported to treat insulin resistance, plasma triglyceride, hyperglycemia, and dyslipidemia in rats through activation of peroxisome proliferator-activated receptors which in turn regulates lipid and glucose metabolism in the body. Hence, ethanolic extract of lemon balm was reported to have potential activity in the prevention and treatment of diabetes mellitus (type-2) and hyperlipidemia [107, 108].

Recently, Lee et al. [109] indicated that a herbal extract of *M. officinalis* not only inhibits visceral obesity but also attenuates the increased fasting blood glucose, impaired glucose tolerance, and pancreatic dysfunction in female obese mice.

5.3. Cardioprotective. *M. officinalis* was reported to have significant cardiovascular effects in heart palpitations along with significant cardioprotective and cardiac tonic activities.

TABLE 2: Clinical studies of *Melissa officinalis*.

Design	Observations	Country	Ref
Randomized, double-blind, placebo-controlled	In this study, the effect of <i>M. officinalis</i> supplementation was evaluated on borderline hyperlipidemia patients. The herbal capsule of <i>M. officinalis</i> extract showed significant results in hyperlipidemic patients. It reduced the level of low-density lipoprotein (LDL) and aspartate transaminase (AST) at the dose of 500 mg (two capsules of <i>M. officinalis</i> three times per day up to 2 months) (trial registration number: IRCT2014042017347N1).	Iran	[138]
Randomized, crossover trial, placebo-controlled	In this study, investigations on safety, tolerability, and pharmacokinetics of a single dose of <i>M. officinalis</i> extract were performed. A single dose of <i>M. officinalis</i> extract containing 500 mg rosmarinic acid seems to be safe and tolerable in healthy individuals. It does not affect liver, kidney, and blood cell functions, and no harmful effects were reported during this study by the patients (trial registration number: UMIN00004997).	Japan	[139]
Randomized, double-blind, placebo-controlled	In this study, the effect of <i>M. officinalis</i> extract was assessed against heart palpitation. Leaf extract of <i>M. officinalis</i> (500 mg two times per day up to 14 days) significantly reduced the incidence of palpitation and the number of anxious patients. It showed safe and beneficial effects in the treatment of palpitation patients, and no side effects were recorded during this study (trial registration number: IRCT2013012712303N1).	Iran	[111]
Prospective pilot study, single-center, open-label	In this study, the effects of Cyracos (standardized extract of <i>M. officinalis</i>) were evaluated against anxiety disorders and sleep disturbance. Chronic administration of leaf extract of <i>M. officinalis</i> (600 mg per day up to 15 days) reduced the stress-related effects including anxiety manifestations (18%), ameliorated anxiety-associated symptoms (15%), and insomnia (42%).	France	[140]
Randomized, double-blind, placebo-controlled	In this study, the effect of <i>M. officinalis</i> oil was estimated against agitation in Alzheimer's disease. Aromatherapy with <i>Melissa</i> oil was not effective compared to the known drug (trial registration number: EudraCT23148/0001/001-0001).	UK	[141]
Randomized, double-blind, placebo-controlled	In this study, anxiolytic effects of the herbal combination were evaluated during the laboratory-induced stress. <i>M. officinalis</i> (80 mg) and <i>Valeriana officinalis</i> (120 mg) were used as a combination, and their 600 mg dose improved the negative effects of the defined intensity stressor simulation on ratings of anxiety.	UK	[142]
Randomized, double-blind, placebo-controlled	In this study, the effectiveness and side effects of <i>M. officinalis</i> with two other herbs were evaluated against infantile colic. After the 1-week treatment of the herbs, crying time was reduced in 85.4% of subjects compared to control (48.9%) and no side effects were recorded during the study.	Italy	[143]
Randomized, double-blind, placebo-controlled	In this study, the effects of <i>M. officinalis</i> on laboratory-induced psychological stress were investigated. The 600 mg dose of herbal extract reduced the negative mood effects of the defined intensity stressor simulation and increased the self-ratings of calmness.	UK	[144]
Randomized, double-blind, placebo-controlled	In this study, the effects of <i>M. officinalis</i> on modulation of mood and cognitive performance were evaluated. The results indicated that doses of <i>Melissa</i> at or above can improve cognitive performance and the dose of 1600 mg showed the best results.	UK	[145]
Randomized, double-blind, placebo-controlled	In this study, the efficacy and safety of <i>M. officinalis</i> extract were evaluated in mild to moderate Alzheimer's disease patients. After the 4-month treatment, herbal extract (60 drops per day) showed a significant outcome on cognitive function compared to control.	Iran	[113]
Randomized, double-blind, placebo-controlled	In this study, the effects of <i>M. officinalis</i> were investigated against herpes simplex infections and the results suggested that the ingredient of the <i>Melissa</i> gave protection against herpes simplex infections and early-stage treatment revealed itself as most effective.	Germany	[146]

This effect is due to the presence of saponins and alkaloids. The cardioprotective effects of aqueous extracts of leaves of *M. officinalis* along with *Lippia alba* (Mill.) (<http://N.E.Br>). ex Britton & P. Wilson and *Cymbopogon citratus* (D.C.) Stapf (concentrations, 0.038, 0.38, 3.8 and 38 mg) was reported in an *in vivo* study on 21 male adult rats to evaluate their activity upon heart rate and cardiac contractile force. The statistical evaluation showed a significant reduction in cardiac rate through muscarinic receptor stimulation while no effect was reported to alter cardiac contractility force [110].

Pharmacological evaluation *M. officinalis* was mainly focused on its antiarrhythmic activity. The administration of ethanolic extract of lemon balm was reported to reduce ventricular fibrillation, tachycardia, and premature beats in CaCl_2 -induced arrhythmias [111]. β -Adrenergic antagonistic activity of lemon balm was reported to have antidysrhythmic activity and induce bradycardia [27, 102].

5.4. Anti-Inflammatory. Reduction in inflammation-induced edema in rat paws has been attributed to the administration of aqueous extract of lemon balm. In addition, the administration of ethanolic extract of *M. officinalis*, mainly attributed to rosmarinic acid content, was reported to exert antinociceptive effects by inhibiting the L-arginine-nitric oxide pathway and activating the cholinergic system [27]. *M. officinalis* ethanol extracted powder mixed with corn starch in 1000 mg capsule form was administered to test the group having dysmenorrhoeal [112]. The severity of pain was significantly reduced from 7.63 to 2.00 in the second menstrual cycle. A remarkable result difference in the first and second menstrual cycle was reported respective to the severity of the pain [113].

5.5. Anticancer. A comparative study of five different extracts of *M. officinalis* was conducted to explore the anticancer effects of this medicinal plant on cell lines by Magalhães et al. [114]. The outcomes of this study sign posted that tumour cells growth was inhibited by employing five different extracts on three types of human tumour cell lines depending on the concentration of *M. officinalis* in the extract. The highlights of this study also revealed an inhibitory effect on tumour cell growth by ethanolic extract due to the presence of rosmarinic acid, with potent penetration power and endorsed *M. officinalis* as a source of bioactive composites with antitumour potential.

Another study was conducted on human colon carcinoma cells to sensitize the *M. officinalis* as a dietary intervention and as a pharmaceutical plant by [115]. The study evidenced that lemon balm methanolic extract prevents the propagation of colon carcinoma cells and self-induce apoptosis in HT-29 and T84 human colon carcinoma cell lines after 3 to 4 days. Another study investigated lemon balm as an antiproliferative agent on different types of cell lines of breast cancer. The outcomes showed that *M. officinalis* extracts have anticancer potential against breast tumours in the cell culture line, due to the presence of the phenolic acids [115]. The recent work of Ghiulai et al. [116] reported how lemon balm extracts prevent breast cancer progression

in vitro and *in vivo* using the chorioallantoic membrane assay.

5.6. Antimicrobial. The discovery and introduction of antibiotics in medicine had a beneficial effect on the control of infectious diseases [117, 118]. Unfortunately, excessive use of antibiotics has been accompanied by the rapid emergence of resistant bacterial strains that are difficult to eradicate and undesirable side effects [7, 119]. As a result, the researchers focused on the discovery of natural bioactives with antibacterial effect but with fewer side effects [120]. Leaf extract of *M. officinalis* was reported to have antimicrobial activity against bacterial strains of 13 test microbes. The antibacterial effect of the essential oil of *M. officinalis* was due to the content of aldehydes, ketones, and monoterpenes [121, 122]. Gram-positive bacteria were reported to exhibit more sensitivity to plant extract than Gram-negative bacteria.

5.7. Antiviral. Oral herpes is caused by the herpes simplex virus type 1 (HSV-1), which enters the body and reactivates, causing an unsightly lesion on the surface of the lips, during periods when the immune system is weakened [15, 123].

A special biological action of *M. officinalis* is antiviral on the herpes virus herpes simplex 1 (HSV-1). This antiviral activity is determined by polyphenolic acids and their derivatives, compounds present in the aqueous extract obtained from the *M. officinalis* leaves. The mechanism of antiviral action involves interaction between polyphenolic compounds, viral proteins, and cell membrane proteins. There is a blockage of membrane receptors (from the cells of the mucosa where the rash is to occur) by polyphenolic compounds, thus preventing the adhesion of the herpes virus-1 to the cell wall and, thus, the beginning of the viral infection spread cycle, after transduction [124].

5.8. Antithyroid Activity. The thyroid gland produces thyroid hormones, which have many functions in the body, one of which is to regulate metabolism [125]. Thyroid diseases are treated with medication and surgery, but there are also natural remedies that can be used for treating these [126]. *In vitro* experiments showed an antithyroid activity for aqueous extracts of *M. officinalis* leaves. Thus, the conversion of T4 to T3, depending on the dose, was observed by action on iodothyronine deiodinase obtained from rat liver microsomes [127]. The effects are dose dependent and are due to caffeic, rosemary, and chlorogenic acids. Compared to some conventional antiviral drugs (idoxuridine), these bioactive compounds from *M. officinalis* cause a shortening of the healing period of herpes lesions and a decrease in the recurrence of viral infection. [127].

6. Clinical Studies

Recently, a research group from Iran reported the effects of *M. officinalis* leaves (in the form of *Melissa* capsule) on anxiety and sleep quality in patients undergoing coronary artery bypass surgery. The clinical trial was conducted on 80 patients, and all patients were given herbal drugs (500 mg of *M. officinalis* leaves) while the placebo control group was given 500 mg of wheat starch three times a day. The

results of seven days of treatment with *M. officinalis* reduced the level of anxiety (49%) and improved the sleep quality (54%) in patients after coronary artery bypass surgery [128].

Watson et al. [129] from Sydney reported the effects of *M. officinalis* essential oil in the treatment of agitated behaviour in older people with and without dementia. A total of 39 nursing home residents with dementia and 10 without dementia participated in this study. Participants were treated with essential oil for two weeks followed by a two-week washout period before commencing the subsequent treatment. Essential oil of *M. officinalis* exhibited more effective in reducing agitation in people without dementia (Trial registration no: ACTRN12614000130662) [129].

Tavares-Silva et al. [130] from Brazil demonstrated the efficacy of *M. officinalis* and *Phytolacca decandra* L. and its combination in the treatment of possible sleep bruxism in children. The clinical trial was conducted on 52 children, based on the parent's report of sleep bruxism. The results of 30 days of treatment with *M. officinalis* reduced the possible sleep bruxism in children, while its combination with *P. decandra* did not improve the results (Trial registration any: NCT02870543) [130].

Nayebi et al. [131] reported the impact of *M. officinalis*-based products in diabetic patients (affected by Type 2 diabetes). The clinical trial was conducted on 37 dyslipidemic diabetic patients, and all the patients were treated with *M. officinalis* or placebo at the dose of two 500 mg, administered as capsules daily in a 3-month timeframe. *M. officinalis* significantly decreased the serum level of triglyceride, and no other metabolic changes were recorded when compared with the control group (Trial registration no: IRCT2015112625251N1) [131].

Asadi et al. [132] demonstrated the antidiabetic activity of hydroalcoholic extract of *M. officinalis* in type 2 diabetic patients. The clinical trial was performed on 62 patients receiving the dose of *Melissa officinalis* or placebo (700 mg per day) twice for 12 weeks. The results of this study indicated that *M. officinalis* extract causes a significant change in fasting blood sugar level, glycated haemoglobin (HbA1c), and systolic blood pressure in comparison with the placebo group. The herbal capsule of *M. officinalis* was safe and effective in enhancement of lipid profile, glycemic control, and reduction of inflammation (Trial registration number: IRCT201701162709N41) [132].

Darvish-Mofrad-Kashani et al. described the efficacy and safety of *M. officinalis* in the improvement of hypoactive sexual desire disorder in women [133]. A total of 89 women suffering from the disease participated in the study and were treated with the aqueous extract of *M. officinalis* or placebo with a dose of two 500 mg capsules per day for 4 weeks. The results of the 4-week study demonstrated that *M. officinalis* extract significantly increased the scores of desire, arousal, lubrication, orgasm, satisfaction, and pain compared to placebo in hypoactive sexual desire disorder in women [133]. Another research group from Iran also discovered the combination of *M. officinalis* and *Nepeta menthoides* Boiss. & Buhse in sleep disorder [134]. A total of 102 patients participated in this study, but only 80 were selected after the screening. Selected patients have been

treated with the dose of 1000 mg of *M. officinalis* plus 400 mg of *N. menthoides* or a placebo for four weeks. The 4-week trial demonstrated that a combination of both showed significant activity against insomnia (Trial registration number: IRCT2015040621592N2) [134].

Oral administration of *M. officinalis* and its impact on biomarkers of oxidative stress, inflammation, and lipid profile in chronic stable angina patients were reported by Javid et al. [135]. The clinical trial was conducted in 80 patients with chronic stable angina and treated with a dose of 3 g per day for 8 weeks. The oral administration of *M. officinalis* powder significantly improved the lipid profile, malondialdehyde (MDA), high sensitivity c reactive protein (hs-CRP), and PNO1 in chronic stable angina patients (Trial registration number: IRCT2016052928152N1) [135]. Perry et al. [136] from the UK reported the effects of a combination of *Salvia officinalis* L., *Rosmarinus officinalis* L., and *M. officinalis* (SRM) against enhancement of memory and brain function in a healthy person. The results of the study demonstrated that an oral administration of SRM combination at the dose of 5 mL two times per day for 2 weeks is more effective when compared with a placebo [136]. Martirelli et al. [137] from Italy reported the effectiveness of *Matricaria chamomilla* L., *M. officinalis* and tyndallized *Lactobacillus acidophilus* (HA122) in infant colic. A total of 176 patients completed the 28-day trial, and crying time was significantly lower in groups A (who was given *M. chamomilla*, *M. officinalis*, and tyndallized *L. acidophilus*) and B (who was given *Lactobacillus reuteri*) when compared with group C (who was given simethicone) at the 28th day. The administration of *M. chamomilla*, *M. officinalis*, and tyndallized *L. acidophilus* showed more effectiveness than that of simethicone in infant colic (Trial registration number: NCT02708238) [137]. Other important clinical trials of *Melissa* genus have been summarized in Table 2.

7. Safety Data

The safety aspects of *M. officinalis* were testified by Haybar et al. [147]. Furthermore, verdicts of potential open-label research trials did not impart any adverse effects after oral consumption of *M. officinalis* 600 mg per day dose. The anxiolytic effects of *M. officinalis* do not affect the circadian activity and are not accompanied by benzodiazepine-specific reactions. However, doses higher than 600 mg extract/day can increase anxiety and negatively affect mood [140].

The outcomes of two more further clinical studies showed no antagonistic effects among the different treatments of experimental studies [146]. Opposing the aforementioned outcomes of different researchers, some other clinical trials observed adverse effects of *M. officinalis* consumption.

A controlled randomized study described cases of vomiting, faintness, wheezing, hyperactiveness, abdominal cramps, and queasiness after drinking 60 drops of *M. officinalis* extract in a 60 days trial [113]. Alijaniha et al. [111] also reported a significant increase in hunger after the *M. officinalis* administering. The 1200 mg dose of *M. officinalis* resulted in causing headache, skin irritation, burning

sensation, increased palpitation rate, and hormone inhibition, particularly thyroid hormone as reported by Ulbricht et al. [148]. In conclusion, utmost attention should be given in case of long-term utilization of this herbal plant concerning the therapy of the above-cited health associated conditions.

8. Therapeutic Perspectives

“Nutraceutical Science” represents a great challenge for the future [149, 150]. An emerging direction was given by nanonutraceuticals that assure their value at a nanolevel as well as safety and efficacy [151, 152]. Nowadays, some emerging applications of nanotechnologies to *Melissa* extracts have been reported [153–155]. For instance, Rostami and Esfahan [155] described the development of a smart edible nanocomposite based on mucilage of *M. officinalis* seed/montmorillonite/curcumin. This may open a novel frontier for the use of this plant and understanding the mechanism of action of its components.

Therapeutic limitations of bioactive natural compounds are represented by possible interactions with other drugs [2, 156]. Regarding drug interactions, *M. officinalis* may have a sedative effect if combined with alcohol, over-the-counter sleep treatments, or prescription sedatives such as clonazepam, lorazepam, phenobarbital, and zolpidem. It may also interact with other medicines levothyroxine (to treat thyroid disorders), warfarin, clopidogrel (anticoagulants), travoprost (antiglaucoma), tamoxifen, and irinotecan (cytostatics). [157].

9. Concluding Remarks

Considering the naturally occurring bioactive molecules with a beneficial potential that can be obtained from plants and herbs, the *Melissa officinalis* is one of the widely used medicinal herbs worldwide. Based on scientific data, *M. officinalis* can be used traditionally for the treatment of several diseases with less toxicity and side effects to support or, in the same cases, as an adjuvant to the conventional pharmacological therapy. The recent researches supported the use of *M. officinalis* for the treatment of certain diseases. Based on this, more researches should be carried out to explore the therapeutic and nutraceutical potential properties of *M. officinalis*. Nevertheless, there is a need for further *in vivo* and *in vitro* research and clinical trials to better understand the related mechanisms of action in the treatment of various diseases.

Data Availability

The data supporting this review are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Authors' Contributions

J.S.-R., N.V.A.K., A.S., M.M., and D.C. conceived, designed and updated the review; C.Q., J.H.-B., M.A., W.A., P.S., S.P., D.A.K., M.A.A., M.I., M.N., B.S., P.P., B.B., P.B., S.M., A.D., and M.L. were responsible for the collection of documents and article writing; J.S.-R., M.M., A.S., N.V.A.K., and D.C. contributed to reviewing the manuscript; J.S.-R. and D.C. edited and amended the final draft of the manuscript. D.C. and J.S.-R. made the revisions of the manuscript. All authors read and approved this version of the manuscript.

References

- [1] J. Sharifi-Rad, A. Bahukhandi, P. Dhyani et al., “Therapeutic potential of neoechinulins and their derivatives: an overview of the molecular mechanisms behind pharmacological activities,” *Frontiers in Nutrition*, vol. 8, article 664197, 2021.
- [2] B. Salehi, S. Sestito, S. Rapposelli et al., “Epibatidine: a promising natural alkaloid in health,” *Biomolecules*, vol. 9, no. 1, p. 6, 2019.
- [3] J. Sharifi-Rad, C. Quispe, M. Imran et al., “Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 3268136, 36 pages, 2021.
- [4] J. Sharifi-Rad, C. Quispe, J. Herrera-Bravo et al., “A pharmacological perspective on plant-derived bioactive molecules for epilepsy,” *Neurochemical Research*, vol. 46, no. 9, pp. 2205–2225, 2021.
- [5] D. Tsoukalas, P. Fragkiadaki, A. O. Docea et al., “Association of nutraceutical supplements with longer telomere length,” *International Journal of Molecular Medicine*, vol. 44, no. 1, pp. 218–226, 2019.
- [6] D. Tsoukalas, O. Zlatian, M. Mitroi et al., “A novel nutraceutical formulation can improve motor activity and decrease the stress level in a murine model of middle-age animals,” *Journal of Clinical Medicine*, vol. 10, no. 4, p. 624, 2021.
- [7] A. F. Burlec, “Essential oils in wellness centers: overview on european union legislation, potential therapeutic effects and toxicity,” *Farmácia*, vol. 68, no. 6, pp. 992–998, 2020.
- [8] A. E. Taiwo, F. B. Leite, G. M. Lucena et al., “Anxiolytic and antidepressant-like effects of *Melissa officinalis* (lemon balm) extract in rats: influence of administration and gender,” *The Indian Journal of Pharmacology*, vol. 44, no. 2, pp. 189–192, 2012.
- [9] “The Plant List, Version 1.1,” 2020, <http://www.theplantlist.org/>.
- [10] W. A. Abdel-Naime, J. R. Fahim, M. A. Fouad, and M. S. Kamel, “Antibacterial, antifungal, and GC-MS studies of *Melissa officinalis*,” *South African Journal of Botany*, vol. 124, no. 7, pp. 228–234, 2019.
- [11] S. Mahajan and N. Tuteja, “Cold, salinity and drought stresses: an overview,” *Archives of Biochemistry and Biophysics*, vol. 444, no. 2, pp. 139–158, 2005.
- [12] P. P. S. Verma, A. Singh, L. Rahaman, and J. R. Bahl, “Lemon balm (*Melissa officinalis* L.) an herbal medicinal plant with broad therapeutic uses and cultivation practices: a review,” *International Journal of Recent Advances in Multidisciplinary Research*, vol. 2, no. 11, pp. 928–933, 2015.

- [13] V. Filipovic and V. Ugrenović, *Lemon balm (Melissa officinalis L.) – technology of cultivation and production cost estimate. International Scientific Meeting, in Sustainable agriculture and rural development in terms of the republic of Serbia strategic goals realization within the Danube region – sustainability and multifunctionality*, J. Subić, Ed., Serbia, Chamber of Commerce and Industry of Serbia, Belgrade Serbia, Belgrade, 2019.
- [14] S. I. Zandalinas, R. Mittler, D. Balfagón, V. Arbona, and A. Gómez-Cadenas, “Plant adaptations to the combination of drought and high temperatures,” *Physiologia Plantarum*, vol. 162, no. 1, pp. 2–12, 2018.
- [15] J. Sharifi-Rad, C. Quispe, A. Rahavian et al., “Bioactive compounds as potential agents for sexually transmitted diseases management: a review to explore molecular mechanisms of action,” *Frontiers in Pharmacology*, vol. 12, p. 12, 2021.
- [16] J. Sharifi-Rad, N. Cruz-Martins, P. López-Jornet et al., “Natural coumarins: exploring the pharmacological complexity and underlying molecular mechanisms,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 6492346, 19 pages, 2021.
- [17] M. Heinrich, G. Appendino, T. Efferth et al., “Best practice in research - Overcoming common challenges in phytopharmacological research,” *Journal of Ethnopharmacology*, vol. 246, article 112230, 2020.
- [18] software, V., “VOSviewer 2021,” 2021, <https://www.vosviewer.com/VOSviewer>.
- [19] I. Koch-Heitzmann and W. Schultze, “Jahre Melissa officinalis,” *Z. Phytotherapie*, vol. 9, no. 3, pp. 77–85, 1988.
- [20] A. Scholey and C. Stough, “11- Neurocognitive effects of herbal extracts,” in *Lifetime Nutritional Influences on Cognition, Behaviour and Psychiatric Illness*, D. Benton, Ed., pp. 272–297, Woodhead Publishing, 2011.
- [21] M.-J. R. Howes and P. J. Houghton, “Traditional medicine for memory enhancement,” in *Herbal Drugs: Ethnomedicine to Modern Medicine*, K. G. Ramawat, Ed., pp. 239–291, Springer Berlin Heidelberg, Berlin, Heidelberg, 2009.
- [22] M. J. R. Howes and P. J. Houghton, “Ethnobotanical treatment strategies against Alzheimer's disease,” *Current Alzheimer Research*, vol. 9, no. 1, pp. 67–85, 2012.
- [23] M. Adams, F. Gmünder, and M. Hamburger, “Plants traditionally used in age related brain disorders—a survey of ethnobotanical literature,” *Journal of Ethnopharmacology*, vol. 113, no. 3, pp. 363–381, 2007.
- [24] K. Patel, S. Pramanik, and V. C. Patil, “Ayurvedic approach with a prospective to treat and prevent Alzheimer's and other cognitive diseases: a review,” *World Journal of Pharmaceutical Sciences*, vol. 3, pp. 234–252, 2014.
- [25] G. B. Hammond, I. D. Fernández, L. F. Villegas, and A. J. Vaisberg, “A survey of traditional medicinal plants from the Callejon de Huaylas, Department of Ancash, Peru,” *Journal of Ethnopharmacology*, vol. 61, no. 1, pp. 17–30, 1998.
- [26] V. Cussy-Poma, E. Fernández, J. Rondevaldova, H. Foffová, and D. Russo, “Ethnobotanical inventory of medicinal plants used in the Qampaya District, Bolivia,” *Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromaticas*, vol. 16, no. 1, pp. 68–77, 2017.
- [27] A. Shakeri, A. Sahebkar, and B. Javadi, “*Melissa officinalis* L. - A review of its traditional uses, phytochemistry and pharmacology,” *Journal of Ethnopharmacology*, vol. 188, pp. 204–228, 2016.
- [28] B. Šarić-Kundalić, C. Dobeš, V. Klatte-Asselmeyer, and J. Saukel, “Ethnobotanical study on medicinal use of wild and cultivated plants in middle, south and west Bosnia and Herzegovina,” *Journal of Ethnopharmacology*, vol. 131, no. 1, pp. 33–55, 2010.
- [29] S. Abbaszadeh, H. Teimouri, and B. Farzan, “An ethnobotanical study of medicinal plants with antianxiety and antidepressant effects in Shahrekord,” *Egyptian Journal of Veterinary Science*, vol. 50, no. 1, pp. 81–87, 2019.
- [30] S. N. Basar and R. Zaman, “An overview of badranjboya (*Melissa officinalis*),” *International Research Journal of Biological Sciences*, vol. 2, no. 12, pp. 107–109, 2013.
- [31] A. Pieroni and C. L. Quave, *Ethnobotany and Biocultural Diversities in the Balkans*, Springer-Verlag, New York, 2014.
- [32] S. A. Baydoun, D. Kanj, K. Raafat, M. Aboul Ela, L. Chalak, and N. Arnold-Apostolides, “Ethnobotanical and economic importance of wild plant species of Jabal Moussa Bioserve, Lebanon,” *Journal of Ecosystem & Ecography*, vol. 7, no. 3, p. 245, 2017.
- [33] A. Ranfa and M. Bodesmo, “An ethnobotanical investigation of traditional knowledge and uses of edible wild plants in the Umbria Region, Central Italy,” *Journal of Applied Botany and Food Quality*, vol. 90, pp. 246–258, 2017.
- [34] D. Estomba, A. Ladio, and M. Lozada, “Medicinal wild plant knowledge and gathering patterns in a Mapuche community from North-Western Patagonia,” *Journal of Ethnopharmacology*, vol. 103, no. 1, pp. 109–119, 2006.
- [35] S. Vogl, P. Picker, J. Mihaly-Bison et al., “Ethnopharmacological *in vitro* studies on Austria's folk medicine –An unexplored lore *in vitro* anti-inflammatory activities of 71 Austrian traditional herbal drugs,” *Journal of Ethnopharmacology*, vol. 149, no. 3, pp. 750–771, 2013.
- [36] J. Savić, M. Mačukanović-Jocić, and S. Jarić, “Medical ethnobotany on the Javor Mountain (Bosnia and Herzegovina),” *European Journal of Integrative Medicine*, vol. 27, pp. 52–64, 2019.
- [37] A. L. B. Zeni and F. Bosio, “Medicinal plants used in Atlantic Forest region, Southern of Santa Catarina-Brazil,” *Revista Brasileira de Farmácia*, vol. 96, no. 1, pp. 1101–1121, 2015.
- [38] G. F. Cavalcante e Costa, H. Nishijo, L. F. Caixeta, and T. A. Aversi-Ferreira, “The confrontation between ethnopharmacology and pharmacological tests of medicinal plants associated with mental and neurological disorders,” *Evidence-based Complementary and Alternative Medicine*, vol. 2018, Article ID 7686913, 27 pages, 2018.
- [39] E. Kozuharova, H. Lebanova, I. Getov, N. Benbassat, and J. Napier, “Descriptive study of contemporary status of the traditional knowledge on medicinal plants in Bulgaria,” *African Journal of Pharmacy and Pharmacology*, vol. 7, no. 5, pp. 185–198, 2013.
- [40] M. A. Bonet, M. Parada, A. Selga, and J. Vallès, “Studies on pharmaceutical ethnobotany in the regions of L'Alt Emporda and Les Guilleries (Catalonia, Iberian Peninsula),” *Journal of Ethnopharmacology*, vol. 68, no. 1-3, pp. 145–168, 1999.
- [41] A. K. Jäger, B. Gauguin, A. Adersen, and L. Gudiksen, “Screening of plants used in Danish folk medicine to treat epilepsy and convulsions,” *Journal of Ethnopharmacology*, vol. 105, no. 1-2, pp. 294–300, 2006.
- [42] V. Tene, O. Malagón, P. V. Finzi, G. Vidari, C. Armijos, and T. Zaragoza, “An ethnobotanical survey of medicinal plants

- used in Loja and Zamora- Chinchipe, Ecuador,” *Journal of Ethnopharmacology*, vol. 111, no. 1, pp. 63–81, 2007.
- [43] J. M. Andrade, H. Lucero Mosquera, and C. Armijos, “Ethnobotany of indigenous Saraguros: medicinal plants used by community healers “Hampiyachakkuna” in the San Lucas Parish, Southern Ecuador,” *BioMed Research International*, vol. 2017, Article ID 9343724, 20 pages, 2017.
- [44] E. E. Tsioutsiou, P. Giordani, E. Hanlidou, M. Biagi, V. de Feo, and L. Cornara, “Ethnobotanical Study of Medicinal Plants Used in Central Macedonia, Greece,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2019, Article ID 4513792, 22 pages, 2019.
- [45] N. A. Al-Douri, “A survey of medicinal plants and their traditional uses in Iraq,” *Pharmaceutical Biology*, vol. 38, no. 1, pp. 74–79, 2000.
- [46] S. A. Ahmad and A. A. Askari, “Ethnobotany of the Hawraman region of Kurdistan Iraq,” *Harvard Papers in Botany*, vol. 20, no. 1, pp. 85–89, 2015.
- [47] M. Nadaf, M. Joharchi, and M. S. Amiri, “Ethnomedicinal uses of plants for the treatment of nervous disorders at the herbal markets of Bojnord, North Khorasan Province, Iran,” *Avicenna Journal of Phytomedicine*, vol. 9, no. 2, pp. 153–163, 2019.
- [48] M. Dolatkahi, A. Dolatkahi, and J. B. Nejad, “Ethnobotanical study of medicinal plants used in Arjan - Parishan protected area in Fars Province of Iran,” *Avicenna Journal of Phytomedicine*, vol. 4, no. 6, pp. 402–412, 2014.
- [49] Z. Sadeghi and A. Mahmood, “Ethno-gynecological knowledge of medicinal plants used by Baluch tribes, southeast of Baluchistan, Iran,” *Revista Brasileira de Farmacognosia*, vol. 24, no. 6, pp. 706–715, 2014.
- [50] R. Tahvilian, S. Shahriari, A. Faramarzi, and A. Komasi, “Ethno-pharmaceutical formulations in Kurdish Ethno-medicine,” *Iranian Journal of Pharmaceutical Research*, vol. 13, no. 3, pp. 1029–1039, 2014.
- [51] C. Guarino, L. De Simone, and S. Santoro, “Ethnobotanical study of the Sannio area, Campania, southern Italy,” *Ethnobotany Research and Applications*, vol. 6, p. 63, 2008.
- [52] A. Pieroni, C. L. Quave, M. L. Villanelli et al., “Ethnopharmacognostic survey on the natural ingredients used in folk cosmetics, cosmeceuticals and remedies for healing skin diseases in the inland marches, Central-Eastern Italy,” *Journal of Ethnopharmacology*, vol. 91, no. 2-3, pp. 331–344, 2004.
- [53] S. Vitalini, F. Tomè, and G. Fico, “Traditional uses of medicinal plants in Valvestino (Italy),” *Journal of Ethnopharmacology*, vol. 121, no. 1, pp. 106–116, 2009.
- [54] M. Idolo, R. Motti, and S. Mazzoleni, “Ethnobotanical and phytomedicinal knowledge in a long-history protected area, the Abruzzo, Lazio and Molise National Park (Italian Apennines),” *Journal of Ethnopharmacology*, vol. 127, no. 2, pp. 379–395, 2010.
- [55] M. Usai, A. D. Atzei, and M. Marchetti, “A comparative study on essential oil intraspecific and seasonal variations: *Melissa romana* Mill. and *Melissa officinalis* L. from Sardinia,” *Chemistry & Biodiversity*, vol. 13, no. 8, pp. 1076–1087, 2016.
- [56] A. Pieroni and V. Cattero, “Wild vegetables do not lie: comparative gastronomic ethnobotany and ethnolinguistics on the Greek traces of the Mediterranean diet of southeastern Italy,” *Acta Botânica Brasílica*, vol. 33, no. 2, pp. 198–211, 2019.
- [57] S. Al-Khalil, “A survey of plants used in Jordanian traditional medicine,” *International Journal of Pharmacognosy*, vol. 33, no. 4, pp. 317–323, 1995.
- [58] F. U. Afifi and B. Abu-Irmaileh, “Herbal medicine in Jordan with special emphasis on less commonly used medicinal herbs,” *Journal of Ethnopharmacology*, vol. 72, no. 1-2, pp. 101–110, 2000.
- [59] B. Mustafa, A. Hajdari, F. Krasniqi et al., “Medical ethnobotany of the Albanian Alps in Kosovo,” *Journal of Ethnobiology and Ethnomedicine*, vol. 8, no. 1, p. 6, 2012.
- [60] S. M. Salah and A. K. Jäger, “Screening of traditionally used Lebanese herbs for neurological activities,” *Journal of Ethnopharmacology*, vol. 97, no. 1, pp. 145–149, 2005.
- [61] B. Rexhepi, A. Bajrami, and B. Mustafa, “Three ethnic groups, one territory: perspectives of an ethnobotanical study from southwestern Macedonia,” *International Journal of Education, Science, Technology, Innovation, Health and Environment*, vol. 4, no. 1, pp. 43–109, 2018.
- [62] A. Merzouki, F. Ed-derfoufi, and J. Molero Mesa, “Contribution to the knowledge of Rifian traditional medicine. II: folk medicine in Ksar Lakbir district (NW Morocco),” *Fitoterapia*, vol. 71, no. 3, pp. 278–307, 2000.
- [63] H. Akdime, S. Boukhira, L. E. Mansouri, and B. D. El AH, “Ethnobotanical study and traditional knowledge of medicinal plants in Ain Leuh region (Middle-Atlas of Morocco),” *American Journal of Advanced Drug Delivery*, vol. 3, no. 3, pp. 248–263, 2015.
- [64] J. M. Neves, C. Matos, C. Moutinho, G. Queiroz, and L. R. Gomes, “Ethnopharmacological notes about ancient uses of medicinal plants in Tras-os-Montes (northern of Portugal),” *Journal of Ethnopharmacology*, vol. 124, no. 2, pp. 270–283, 2009.
- [65] B. Rexhepi, B. Mustafa, A. Hajdari, J. Rushidi-Rexhepi, C. L. Quave, and A. Pieroni, “Traditional medicinal plant knowledge among Albanians, Macedonians and Gorani in the Sharr Mountains (Republic of Macedonia),” *Genetic Resources and Crop Evolution*, vol. 60, no. 7, pp. 2055–2080, 2013.
- [66] N. S. Sokolova, T. G. Panfilova, and G. A. Panfilov, “Wild and cultivated plants in traditional medicine,” Moscow, 1990.
- [67] S. Jarić, Z. Popović, M. Maćukanović-Jocić et al., “An ethnobotanical study on the usage of wild medicinal herbs from Kopaonik Mountain (Central Serbia),” *Journal of Ethnopharmacology*, vol. 111, no. 1, pp. 160–175, 2007.
- [68] R. Alarcón, M. Pardo-de-Santayana, C. Priestley, R. Morales, and M. Heinrich, “Medicinal and local food plants in the south of Alava (Basque Country, Spain),” *Journal of Ethnopharmacology*, vol. 176, pp. 207–224, 2015.
- [69] S. Karaman and Y. Z. Kocabas, “Traditional medicinal plants of K. Maras (Turkey),” *The Sciences*, vol. 1, no. 3, pp. 125–128, 2001.
- [70] G. Bulut and E. Tuzlacı, “An ethnobotanical study of medicinal plants in Bayramiç,” *Marmara Pharmaceutical Journal*, vol. 19, no. 3, pp. 268–282, 2015.
- [71] Y. Güzel, M. Güzelşemme, and M. Miski, “Ethnobotany of medicinal plants used in Antakya: a multicultural district in Hatay Province of Turkey,” *Journal of Ethnopharmacology*, vol. 174, pp. 118–152, 2015.
- [72] Y. E. Arican, Y. Yesil, and G. E. Genç, “A preliminary ethnobotanical survey of Kumluca (Antalya),” *Journal of Faculty Pharmacy of Istanbul University*, vol. 43, no. 2, pp. 95–102, 2013.

- [73] S. Ari, M. Temel, and M. Konuk, "An ethnobotanical approach to MRSA (methicillin-resistant *Staphylococcus aureus*) in Western Anatolia: a case of Afyonkarahisar," *Indian Journal of Traditional Knowledge*, vol. 16, no. 1, pp. 35–43, 2017.
- [74] F. Günes, "Medicinal plants used in the Uzunköprü district of Edirne, Turkey," *Acta Societatis Botanicorum Poloniae*, vol. 86, no. 4, p. 3565, 2017.
- [75] Ü. Mumcu and H. Korkmaz, "Ethnobotanical uses of alien and native plant species of Yf_imIrmak Delta, Samsun, Turkey," *Turkish Journal of Biology*, vol. 31, no. 3, pp. 102–113, 2018.
- [76] S. Mart and N. Türkmen, "A survey on wild plants with ethnobotanical use in the Bahçe and Hasanbeyli districts of Osmaniye, Turkey," *GSC Biological and Pharmaceutical Sciences*, vol. 5, no. 3, pp. 028–035, 2018.
- [77] S. Demirci and N. Ozhatay, "An ethnobotanical study in Kahramanmaraş (Turkey); wild plants used for medicinal purpose in Andırın, Kahramanmaraş," *Turkish Journal of Pharmaceutical Sciences*, vol. 9, no. 1, pp. 75–92, 2012.
- [78] D. Egamberdieva, N. Mamadalieva, O. Khodjimatomov, and A. Tiezzi, "Medicinal plants from Chatkal Biosphere Reserve used for folk medicine in Uzbekistan," *Medicinal and Aromatic Plant Science and Biotechnology*, vol. 7, no. 1, pp. 56–64, 2013.
- [79] E. A. Luta, M. Ghica, T. Costea, and C. Elena, "Phytosociological study and its influence on the biosynthesis of active compounds of two medicinal plants *Mentha piperita* L. AND *MELISSA OFFICINALIS* L.," *Farmácia*, vol. 68, no. 5, pp. 919–924, 2020.
- [80] D. Acevedo, M. Navarro, and P. Montero, "Composición química del aceite esencial de las hojas de toronjil (*Melissa officinalis* L.)," *Información Tecnológica*, vol. 24, no. 4, pp. 11–12, 2013.
- [81] R. Awad, A. Muhammad, T. Durst, V. L. Trudeau, and J. T. Arnason, "Bioassay-guided fractionation of lemon balm (*Melissa officinalis* L.) using an in vitro measure of GABA transaminase activity," *Phytotherapy Research*, vol. 23, no. 8, pp. 1075–1081, 2009.
- [82] A. Astani, J. Reichling, and P. Schnitzler, "Melissa officinalis extract inhibits attachment of herpes simplex virus In Vitro," *Chemotherapy*, vol. 58, no. 1, pp. 70–77, 2012.
- [83] J. P. Kamdem, A. Adeniran, A. A. Boligon et al., "Antioxidant activity, genotoxicity and cytotoxicity evaluation of lemon balm (*Melissa officinalis* L.) ethanolic extract: Its potential role in neuroprotection," *Industrial Crops and Products*, vol. 51, pp. 26–34, 2013.
- [84] P. Aubert, I. Guinobert, C. Blondeau et al., "Basal and spasmolytic effects of a hydroethanolic leaf extract of *Melissa officinalis* L. on intestinal motility: An Ex Vivo Study," *Journal of Medicinal Food*, vol. 22, no. 7, pp. 653–662, 2019.
- [85] A. Binello, G. Cravotto, L. Boffa et al., "Efficient and selective green extraction of polyphenols from lemon balm," *Comptes Rendus Chimie*, vol. 20, no. 9–10, pp. 921–926, 2017.
- [86] J. Adinee, K. Piri, and O. Karami, "Essential oil component in flower of lemon balm (*Melissa officinalis* L.)," *American Journal of Biochemistry and Biotechnology*, vol. 4, no. 3, pp. 277–278, 2008.
- [87] M. Adam, P. Dobiáš, P. Pavlíková, and K. Ventura, "Comparison of solid-phase and single-drop microextractions for headspace analysis of herbal essential oils," *Central European Journal of Chemistry*, vol. 7, no. 3, pp. 303–311, 2009.
- [88] S. Afsharypuor, F. Alijaniha, M. Mosaddegh et al., "Essential oil constituents of leaf, flower and stem of *Melissa officinalis* L. grown in Gonbad-Kavus (Iran)," *Journal of Essential Oil-Bearing Plants*, vol. 18, no. 2, pp. 460–463, 2015.
- [89] F. Abdellatif, H. Boudjella, A. Zitouni, and A. Hassani, "Chemical composition and antimicrobial activity of the essential oil from leaves of Algerian *Melissa officinalis* L.," *EXCLI Journal*, vol. 13, pp. 772–781, 2014.
- [90] F. Abdellatif and A. Hassani, "Chemical composition of the essential oils from leaves of *Melissa officinalis* extracted by hydrodistillation, steam distillation, organic solvent and microwave hydrodistillation," *Journal of Materials and Environmental Science*, vol. 6, no. 1, pp. 207–213, 2015.
- [91] S. Barakat, M. Hudaib, N. el-asadand, and D. Burns, "Composition of volatile oil and methanolic extract of Jordanian *Melissa Officinalis* L. and actions Against human cancer cell lines," *Oriental Journal of Chemistry*, vol. 32, no. 5, pp. 2355–2362, 2016.
- [92] A. A. Efremov, I. D. Zykova, and A. E. Gorbachev, "Composition of the essential oil from the lemon balm growing in the neighborhood of Krasnoyarsk as indicated by gas chromatography–mass spectrometry data," *Russian Journal of Bioorganic Chemistry*, vol. 42, no. 7, pp. 726–729, 2016.
- [93] S.-U. Rehman, R. Latief, K. A. Bhat, M. A. Khuroo, A. S. Shawl, and S. Chandra, "Comparative analysis of the aroma chemicals of *Melissa officinalis* using hydrodistillation and HS-SPME techniques," *Arabian Journal of Chemistry*, vol. 10, pp. S2485–S2490, 2017.
- [94] G. Khalili, A. Mazloomifar, K. Larijani, M. S. Tehrani, and P. A. Azar, "Solvent-free microwave extraction of essential oils from *Thymus vulgaris* L. and *Melissa officinalis* L.," *Industrial Crops and Products*, vol. 119, pp. 214–217, 2018.
- [95] M. R. Sepand, M. Soodi, H. Hajimehdipoor, M. Soleimani, and E. Sahraei, "Comparison of neuroprotective effects of *Melissa officinalis* total extract and its acidic and non-acidic fractions against a β -induced toxicity," *Iranian Journal of Pharmaceutical Research*, vol. 12, no. 2, pp. 415–423, 2013.
- [96] M. Bayat, A. Azami Tameh, M. Hossein Ghahremani et al., "Neuroprotective properties of *Melissa officinalis* after hypoxic-ischemic injury both In Vitro and In Vivo," *DARU Journal of Pharmaceutical Sciences*, vol. 20, no. 1, p. 42, 2012.
- [97] M. Soodi, N. Naghdi, H. Hajimehdipoor, S. Choopani, and E. Sahraei, "Memory-improving activity of *Melissa officinalis* extract in naïve and scopolamine-treated rats," *Research in Pharmaceutical Sciences*, vol. 9, no. 2, pp. 107–114, 2014.
- [98] P. Mirabi, M. Namdari, S. Alamolhoda, and F. Mojab, "The effect of *Melissa Officinalis* extract on the severity of primary dysmenorrhea," *Iranian Journal of Pharmaceutical Research*, vol. 16, Suppl, pp. 171–177, 2017.
- [99] L. Nussbaum, L. M. Hoge, D. A. Călina et al., "Modern treatment approaches in psychoses. Pharmacogenetic, neuroimaging and clinical implications," *Farmácia*, vol. 65, no. 1, pp. 75–81, 2017.
- [100] L. Dehelean, A. M. Romoşan, M. Andor et al., "Clinical factors influencing antipsychotic choice, dose and augmentation in patients treated with long acting antipsychotics," *Farmácia*, vol. 68, no. 1, pp. 35–41, 2020.
- [101] K. Dastmalchi, H. J. Damien Dorman, P. P. Oinonen, Y. Darwis, I. Laakso, and R. Hiltunen, "Chemical composition

- and *in vitro* antioxidative activity of a lemon balm (*Melissa officinalis* L.) extract,” *Science and Technology*, vol. 41, no. 3, pp. 391–400, 2008.
- [102] E. A. Moacă, C. Farcaș, A. Ghițu et al., “A comparative study of *Melissa officinalis* leaves and stems ethanolic extracts in terms of antioxidant, cytotoxic, and antiproliferative potential,” *Evidence-based Complementary and Alternative Medicine*, vol. 2018, Article ID 7860456, 12 pages, 2018.
- [103] R. P. Pereira, R. Fachineto, A. de Souza Prestes et al., “Antioxidant effects of different extracts from *Melissa officinalis*, *Matricaria recutita* and *Cymbopogon citratus*,” *Neurochemical Research*, vol. 34, no. 5, pp. 973–983, 2009.
- [104] M. J. Chung, S. Y. Cho, M. J. H. Bhuiyan, K. H. Kim, and S. J. Lee, “Anti-diabetic effects of lemon balm (*Melissa officinalis*) essential oil on glucose- and lipid-regulating enzymes in type 2 diabetic mice,” *British Journal of Nutrition*, vol. 104, no. 2, pp. 180–188, 2010.
- [105] A. Zeraatpishe, S. Oryan, Mohammad Hadi Bagheri et al., “Effects of *Melissa officinalis* L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation,” *Toxicology and Industrial Health*, vol. 27, no. 3, pp. 205–212, 2011.
- [106] S. Changizi Ashtiyani, A. Zarei, S. Taheri, A. Rezaei, M. Golshan, and R. Ghafarzadegan, “A comparative study of hypolipidemic activities of the extracts of *Melissa officinalis* and *Berberis vulgaris* in rats,” *فصلنامه علمی پژوهشی گیاهان دارویی*, vol. 3, no. 47, pp. 38–47, 2013.
- [107] H.-J. Jun, J. H. Lee, Y. Jia et al., “*Melissa officinalis* essential oil reduces plasma triglycerides in human apolipoprotein E2 transgenic mice by inhibiting sterol regulatory element-binding protein-1c-dependent fatty acid synthesis,” *The Journal of Nutrition*, vol. 142, no. 3, pp. 432–440, 2012.
- [108] C. Weidner, S. J. Wowro, A. Freiwald et al., “Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice,” *Molecular Nutrition & Food Research*, vol. 58, no. 4, pp. 903–907, 2014.
- [109] D. Lee, Y. Shin, J. Jang et al., “The herbal extract ALS-L1023 from *Melissa officinalis* alleviates visceral obesity and insulin resistance in obese female C57BL/6J mice,” *Journal of Ethnopharmacology*, vol. 253, p. 112646, 2020.
- [110] R. Gazola, D. Machado, C. Ruggiero, G. Singi, and M. Macedo Alexandre, “*Lippia alba*, *Melissa officinalis* and *Cymbopogon citratus*: effects of the aqueous extracts on the isolated hearts of rats,” *Pharmacological Research*, vol. 50, no. 5, pp. 477–480, 2004.
- [111] F. Alijaniha, M. Naseri, S. Afsharypour et al., “Heart palpitation relief with *Melissa officinalis* leaf extract: Double blind, randomized, placebo controlled trial of efficacy and safety,” *Journal of Ethnopharmacology*, vol. 164, pp. 378–384, 2015.
- [112] A. Carnat, A. Carnat, D. Fraisse, and J. L. Lamaison, “The aromatic and polyphenolic composition of lemon balm (*Melissa officinalis* L. subsp. *officinalis*) tea,” *Pharmaceutica Acta Helveticae*, vol. 72, no. 5, pp. 301–305, 1998.
- [113] S. Akhondzadeh, M. Noroozian, M. Mohammadi, S. Ohadinia, A. H. Jamshidi, and M. Khani, “*Melissa officinalis* extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial,” *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 74, no. 7, pp. 863–866, 2003.
- [114] D. B. Magalhães, I. Castro, V. Lopes-Rodrigues et al., “*Melissa officinalis* L. Ethanolic extract inhibits the growth of a lung cancer cell line by interfering with the cell cycle and inducing apoptosis,” *Food & Function*, vol. 9, no. 6, pp. 3134–3142, 2018.
- [115] C. Weidner, M. Rousseau, A. Plauth et al., “*Melissa officinalis* extract induces apoptosis and inhibits proliferation in colon cancer cells through formation of reactive oxygen species,” *Phytomedicine*, vol. 22, no. 2, pp. 262–270, 2015.
- [116] R. Ghiulai, S. Avram, D. Stoian et al., “Lemon balm extracts prevent breast cancer progression *in vitro* and *in ovo* on chorioallantoic membrane assay,” *Evidence-based Complementary and Alternative Medicine: Ecam*, vol. 2020, article 6489159, 17 pages, 2020.
- [117] Y. Taheri, N. Joković, J. Vitorović, O. Grundmann, A. Maroyi, and D. Calina, “The burden of the serious and difficult-to-treat infections and a new antibiotic available: cefiderocol,” *Frontiers in Pharmacology*, vol. 11, p. 18, 2021.
- [118] A. E. Ghenea, R. Cioboată, A. I. Drocaș et al., “Prevalence and antimicrobial resistance of *Klebsiella* strains isolated from a county hospital in Romania,” *Antibiotics*, vol. 10, no. 7, p. 868, 2021.
- [119] O. Zlatian, A. T. Balasoiu, M. Balasoiu et al., “Antimicrobial resistance in bacterial pathogens among hospitalised patients with severe invasive infections,” *Experimental and Therapeutic Medicine*, vol. 16, no. 6, pp. 4499–4510, 2018.
- [120] J. Sharifi-Rad, A. Dey, N. Koirala et al., “Cinnamomum species: bridging phytochemistry knowledge, pharmacological properties and toxicological safety for health benefits,” *Frontiers in Pharmacology*, vol. 12, pp. 600139–600139, 2021.
- [121] N. Mimica-Dukic, B. Bozin, M. Sokovic, and N. Simin, “Antimicrobial and antioxidant activities of *Melissa officinalis* L. (Lamiaceae) essential oil,” *Journal of Agricultural and Food Chemistry*, vol. 52, no. 9, pp. 2485–2489, 2004.
- [122] A. Ponce, R. Fritz, C. del Valle, and S. I. Roura, “Antimicrobial activity of essential oils on the native microflora of organic Swiss chard,” *LWT- Food Science and Technology*, vol. 36, no. 7, pp. 679–684, 2003.
- [123] D. Boda, A. O. Docea, D. Calina et al., “Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (review),” *International Journal of Oncology*, vol. 52, no. 3, pp. 637–655, 2018.
- [124] A. Astani, J. Reichling, and P. Schnitzler, “*Melissa officinalis* extract inhibits attachment of herpes simplex virus *in vitro*,” *Chemotherapy*, vol. 58, no. 1, pp. 70–77, 2012.
- [125] D. Calina, A. Docea, K. Golokhvast, S. Sifakis, A. Tsatsakis, and A. Makriganakis, “Management of endocrinopathies in pregnancy: a review of current evidence,” *International Journal of Environmental Research and Public Health*, vol. 16, no. 5, p. 781, 2019.
- [126] S. Amir, S. T. A. Shah, C. Mamoulakis et al., “Endocrine disruptors acting on estrogen and androgen pathways cause reproductive disorders through multiple mechanisms: a review,” *International Journal of Environmental Research and Public Health*, vol. 18, no. 4, p. 1464, 2021.
- [127] D. Kaplan and C. Dosiou, “Two cases of graves’ hyperthyroidism treated with homeopathic remedies containing herbal extracts from *Lycopus* spp. and *Melissa officinalis*,” *Journal of the Endocrine Society*, vol. 5, Supplement_1, pp. A971–A971, 2021.
- [128] A. Soltanpour, F. Alijaniha, M. Naseri, A. Kazemnejad, and M. R. Heidari, “Effects of *Melissa officinalis* on anxiety and sleep quality in patients undergoing coronary artery bypass surgery: A double-blind randomized placebo controlled

- trial,” *European Journal of Integrative Medicine*, vol. 28, pp. 27–32, 2019.
- [129] K. Watson, D. Hatcher, and A. Good, “A randomised controlled trial of Lavender (*Lavandula Angustifolia*) and Lemon Balm (*Melissa Officinalis*) essential oils for the treatment of agitated behaviour in older people with and without dementia,” *Complementary Therapies in Medicine*, vol. 42, pp. 366–373, 2019.
- [130] C. Tavares-Silva, C. Holandino, F. Homsani et al., “Homeopathic medicine of *Melissa officinalis* combined or not with *Phytolacca decandra* in the treatment of possible sleep bruxism in children: A crossover randomized triple-blinded controlled clinical trial,” *Phytomedicine*, vol. 58, p. 152869, 2019.
- [131] N. Nayebi, A. Esteghamati, A. Meysamie et al., “The effects of a *Melissa officinalis* L. based product on metabolic parameters in patients with type 2 diabetes mellitus: a randomized double-blinded controlled clinical trial,” *Journal of Complementary and Integrative Medicine*, vol. 16, no. 3, 2019.
- [132] A. Asadi, F. Shidfar, M. Safari et al., “Efficacy of *Melissa officinalis* L. (lemon balm) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a randomized, double-blind, clinical trial,” *Phytotherapy Research*, vol. 33, no. 3, pp. 651–659, 2019.
- [133] Z. Darvish-Mofrad-Kashani, E. Emaratkar, F. Hashem-Dabaghian et al., “Effect of *Melissa officinalis* (lemon balm) on sexual dysfunction in women: a double-blind, randomized, placebo-controlled study,” *The Iranian Journal of Pharmaceutical Research*, vol. 17, Suppl, pp. 89–100, 2018.
- [134] M. Ranjbar, A. Salehi, H. Rezaeizadeh et al., “Efficacy of a combination of *Melissa officinalis* L. and *Nepeta menthoides* Boiss. & Buhse on insomnia: a triple-blind, randomized placebo-controlled clinical trial,” *Journal of Alternative and Complementary Medicine*, vol. 24, no. 12, pp. 1197–1203, 2018.
- [135] A. Z. Javid, H. Haybar, P. Dehghan et al., “The effects of *Melissa officinalis* (lemon balm) in chronic stable angina on serum biomarkers of oxidative stress, inflammation and lipid profile,” *Asia Pacific Journal of Clinical Nutrition*, vol. 27, no. 4, pp. 785–791, 2018.
- [136] N. S. L. Perry, R. Menzies, F. Hodgson et al., “A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age,” *Phytomedicine*, vol. 39, pp. 42–48, 2018.
- [137] M. Martinelli, D. Ummarino, F. P. Giugliano et al., “Efficacy of a standardized extract of *Matricariae chamomilla* L., *Melissa officinalis* L. and tyndallized *Lactobacillus acidophilus* (HA122) in infantile colic: an open randomized controlled trial,” *Neurogastroenterology and Motility*, vol. 29, no. 12, 2017.
- [138] P. Jandaghi, M. Noroozi, H. Ardalani, and M. Alipour, “Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia—A randomized double-blind placebo-controlled clinical trial,” *Complementary Therapies in Medicine*, vol. 26, pp. 136–140, 2016.
- [139] M. Noguchi-Shinohara, K. Ono, T. Hamaguchi et al., “Pharmacokinetics, safety and tolerability of melissa officinalis extract which contained rosmarinic acid in healthy individuals: a randomized controlled trial,” *PLoS One*, vol. 10, no. 5, article e0126422, 2015.
- [140] J. Cases, A. Ibarra, N. Feuillère, M. Roller, and S. G. Sukkar, “Pilot trial of *Melissa officinalis* L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances,” *Mediterranean Journal of Nutrition and Metabolism*, vol. 4, no. 3, pp. 211–218, 2011.
- [141] A. Burns, E. Perry, C. Holmes et al., “A double-blind placebo-controlled randomized trial of *Melissa officinalis* oil and donepezil for the treatment of agitation in Alzheimer’s disease,” *Dementia and Geriatric Cognitive Disorders*, vol. 31, no. 2, pp. 158–164, 2011.
- [142] D. O. Kennedy, W. Little, C. F. Haskell, and A. B. Scholey, “Anxiolytic effects of a combination of *Melissa officinalis* and *Valeriana officinalis* during laboratory induced stress,” *Phytotherapy Research*, vol. 20, no. 2, pp. 96–102, 2006.
- [143] F. Savino, F. Cresi, E. Castagno, L. Silvestro, and R. Oggero, “A randomized double-blind placebo-controlled trial of a standardized extract of *Matricariae recutita*, *Foeniculum vulgare* and *Melissa officinalis* (ColiMil®) in the treatment of breastfed colicky infants,” *Phytotherapy Research*, vol. 19, no. 4, pp. 335–340, 2005.
- [144] D. O. Kennedy, W. Little, and A. B. Scholey, “Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (lemon balm),” *Psychosomatic Medicine*, vol. 66, no. 4, pp. 607–613, 2004.
- [145] D. O. Kennedy, G. Wake, S. Savelev et al., “Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of *Melissa Officinalis* (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties,” *Neuropsychopharmacology*, vol. 28, no. 10, pp. 1871–1881, 2003.
- [146] R. Wölbling and K. Leonhardt, “Local therapy of herpes simplex with dried extract from *Melissa officinalis*,” *Phytomedicine*, vol. 1, no. 1, pp. 25–31, 1994.
- [147] H. Haybar, A. Z. Javid, M. H. Haghighizadeh, E. Valizadeh, S. M. Mohaghegh, and A. Mohammadzadeh, “The effects of *Melissa officinalis* supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina,” *Clinical Nutrition ESPEN*, vol. 26, pp. 47–52, 2018.
- [148] C. Ulbricht, T. Brendler, J. Gruenwald et al., “Lemon balm (*Melissa officinalis* L.): an evidence-based systematic review by the Natural Standard Research Collaboration,” *Journal of Herbal Pharmacotherapy*, vol. 5, no. 4, pp. 71–114, 2005.
- [149] J. Sharifi-Rad, S. Kamiloglu, B. Yeskalyeva et al., “Pharmacological activities of psoralidin: a comprehensive review of the molecular mechanisms of action,” *Frontiers in Pharmacology*, vol. 11, p. 11, 2020.
- [150] M. S. Islam, C. Quispe, R. Hossain et al., “Neuropharmacological effects of quercetin: a literature-based review,” *Frontiers in Pharmacology*, vol. 12, p. 1533, 2021.
- [151] D. Tsoukalas, P. Fragkiadaki, A. O. Docea et al., “Discovery of potent telomerase activators: unfolding new therapeutic and anti-aging perspectives,” *Molecular Medicine Reports*, vol. 20, no. 4, pp. 3701–3708, 2019.
- [152] M. T. Islam, C. Quispe, M. Martorell et al., “Dietary supplements, vitamins and minerals as potential interventions against viruses: perspectives for COVID-19,” *International Journal for Vitamin and Nutrition Research*, pp. 1–18, 2021.
- [153] M. Bordbar, N. Negahdar, and M. Nasrollahzadeh, “*Melissa Officinalis* L. leaf extract assisted green synthesis of CuO/ZnO nanocomposite for the reduction of 4-nitrophenol and Rhodamine B,” *Separation and Purification Technology*, vol. 191, pp. 295–300, 2018.

- [154] Z. Rezaei, S. Jafarirad, and M. Kosari-Nasab, "Modulation of secondary metabolite profiles by biologically synthesized MgO/perlite nanocomposites in *Melissa officinalis* plant organ cultures," *Journal of Hazardous Materials*, vol. 380, p. 120878, 2019.
- [155] H. Rostami and A. A. Esfahani, "Development a smart edible nanocomposite based on mucilage of *Melissa officinalis* seed/montmorillonite (MMT)/curcumin," *International Journal of Biological Macromolecules*, vol. 141, pp. 171–177, 2019.
- [156] B. Salehi, A. Prakash Mishra, M. Nigam et al., "Ficus plants: state of the art from a phytochemical, pharmacological, and toxicological perspective," *Phytotherapy Research*, vol. 35, no. 3, pp. 1187–1217, 2021.
- [157] J. Ghazizadeh, S. Sadigh-Eteghad, W. Marx et al., "The effects of lemon balm (*Melissa officinalis* L.) on depression and anxiety in clinical trials: a systematic review and meta-analysis," *Phytotherapy Research*, pp. 1–6, 2021.